Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Eli Lilly -- Ignore unavailable to you. Want to Upgrade?

To: Bull-like who wrote (309)	9/3/1998 7:57:00 PM
From: Anthony Wong	Respond to of 642

Da Bull, it's about time for LLY to do some catching up; nothing but good news recently. I've once owned CCI, CMB and AXP (some 8 years ago) and have regretted selling them. I am sorely tempted to buy them back at today's price, but with the recent bearishness on money-centered banks and financials, I think they'll have more to go before they bottom out. Maybe I'll do some dollar-cost averaging. Also looking at DIS and CA. Anthony

To: Bull-like who wrote (309)	9/3/1998 8:09:00 PM
From: Anthony Wong	Respond to of 642

09/03 18:43 Inhale drug system holds fans - Business Week NEW YORK, Sept 3 (Reuters) - Inhale Therapeutic Systems Inc. <INHL.O> may have seen its stock drop of late, but its fans remain bullish on the company, according to the Sept. 7 issues of Business Week. Pfizer Inc. <PFE.N>, Eli Lilly & Co. <LLY.N> and Baxter International Inc. <BAX.N> have all invested in Inhale, which makes a pulmonary device that would allow for delivery of drugs through inhalation. Pfizer has a 5 percent stake in Inhale and has conducted tests for an inhaled insulin. A third clinical trial is scheduled for November, Business Week said. Baxter spend $20 million in March 1996 to co-develop compounds for Inhale's pulmonary system. Lilly paid $10 million for an inhaled osteoporosis agent and another undisclosed compound, the magazine said. "Inhale's outstanding - but low-risk - opportunity in pulmonary delivery is undervalued by the market," Peter Ginsburg of the Minneapolis investment firm Piper-Jaffray told Business Week. Ginsburg estimates sales of drugs that can be switched to the pulmonary route could top $10 billion, the magazine said. Inhale stock closed down 3/8 at 23-1/4 on the Nasdaq Thursday. Business Week said it hit 37-1/4 last October.

To: Bull-like who wrote (309)	9/4/1998 7:53:00 AM
From: Anthony Wong	Read Replies (1) \| Respond to of 642

Synaptic, Eli Lilly rise on migraine drug advance By Mary Kennedy, CBS MarketWatch Last Update: 4:19 PM ET Sep 3, 1998 NewsWatch PARAMUS, N.J. (CBS.MW) -- Shares of Synaptic Pharmaceutical rose 20 percent and Eli Lilly shares gained 4.4 percent Thursday on news that a molecule for treatment of migraine headaches which they are developing will advance to the next phase of clinical trials. Synaptic (SNAP) and Lilly (LLY) said in a statement that they will form a product team to pursue commercial development of the molecule. The companies estimate the market for migraine drugs is about $1.2 billion and could grow to $3 billion by 2000. Shares of Synaptic closed up 2 1/8 to 13 and Eli Lilly rose 3 1/16 to 72 5/16. "Clearly, this event is a very satisfactory reward for the members of the serotonin team from both companies whose work has contributed to the progress of the program," said Kathleen P. Mullinix, Ph.D., chairman and chief executive officer of Synaptic. Migraine headaches include throbbing headpain in conjunction with nausea, vomiting and occasionally blackouts. It is believed that as much as 10 percent of the world suffers from migraines. Synaptic is developing a process to discover and clone human receptor genes associated with specific disorders and to create specific compounds to treat those ailments. Synaptic is working with three other pharmaceutical companies in addition to Eli Lilly. Lilly, based in Indianapolis, Ind., is best known for its Prozac anti-depressant drug. Mary Kennedy is a reporter for CBS MarketWatch. cbs.marketwatch.com